Lipocine (LPCN) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$26.3 million.
- Lipocine's Enterprise Value rose 2676.68% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.3 million, marking a year-over-year increase of 2676.68%. This contributed to the annual value of -$37.0 million for FY2024, which is 564.24% up from last year.
- As of Q3 2025, Lipocine's Enterprise Value stood at -$26.3 million, which was up 2676.68% from -$29.5 million recorded in Q2 2025.
- Lipocine's Enterprise Value's 5-year high stood at -$26.3 million during Q3 2025, with a 5-year trough of -$87.4 million in Q4 2021.
- Its 5-year average for Enterprise Value is -$52.3 million, with a median of -$46.0 million in 2024.
- Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 34537.58% in 2021, then soared by 3617.83% in 2023.
- Quarter analysis of 5 years shows Lipocine's Enterprise Value stood at -$87.4 million in 2021, then increased by 29.72% to -$61.5 million in 2022, then surged by 36.18% to -$39.2 million in 2023, then increased by 5.64% to -$37.0 million in 2024, then grew by 28.95% to -$26.3 million in 2025.
- Its Enterprise Value was -$26.3 million in Q3 2025, compared to -$29.5 million in Q2 2025 and -$36.1 million in Q1 2025.